Novo Nordisk is a global healthcare company founded in Denmark in 1923, with nearly a century of experience pioneering treatments for serious chronic diseases. Today, the company employs more than 77,000 people across approximately 80 countries, and its products are available in markets worldwide. With a strong heritage in diabetes care and insulin innovation, Novo Nordisk has broadened its focus to address obesity, rare blood and endocrine disorders, and is advancing new therapies in areas such as cardiovascular disease, chronic kidney disease, and Alzheimer’s. The company remains committed to preventing chronic diseases on all fronts. For more information, visit novonordisk.com.
